Welcome to the Opioid Industry Documents Archive, a collaboration between the University of California, San Francisco and Johns Hopkins University.
The opioid epidemic is the worst drug epidemic in our nation’s history, and nothing is more important to those who have been impacted than the truth – full transparency regarding how the epidemic occurred and how further harms can be abated. There are many other pressing questions as well, with answers that lie within documents from government litigation against pharmaceutical companies, including opioid manufacturers and distributors, as well as litigation taking place in federal court on behalf of thousands of cities and counties in the United States.
These documents have been publicly released through state and federal investigations, settlement agreements, and other proceedings, including a lawsuit filed by The Washington Post and the Charleston Gazette. The documents include emails, memos, presentations, sales reports, budgets, audit reports, Drug Enforcement Administration briefings, meeting agendas and minutes, expert witness reports, and depositions of drug company executives. The archive serves as a living repository of information that can be used to learn from the opioid epidemic so as to improve and safeguard public policy and public health, and to ensure that the opioid-related harms that have taken place never occur again.
Our ultimate goal is to consolidate all opioid litigation documents – and potentially additional information from sources such as the U.S. Food and Drug Administration, professional societies, and individuals and family members directly impacted by the epidemic - into a universally accessible and easy-to-use digital archive for the benefit of individuals and communities, researchers, journalists, policymakers and other stakeholders affected by the opioid crisis. This resource provides immediate access to currently available documents and other information under the umbrella of the UCSF Industry Documents Library.
The Opioid Industry Documents Archive leverages extraordinary expertise within the University of California, San Francisco and Johns Hopkins University in library science, informational technology, and digital archiving, as well as scholarship focused on many dimensions of the opioid epidemic ranging from the history of medicine to pharmaceutical policy to clinical care, including through the UCSF Philip R. Lee Institute for Health Policy Studies, the Department of Clinical Pharmacy, the Department of Humanities and Social Sciences, the Department of Family and Community Medicine, and the UCSF Library, as well as Johns Hopkins Bloomberg School of Public Health's Center for Drug Safety and Effectiveness, the Johns Hopkins Welch Medical Library, the Institute of the History of Medicine, and the Sheridan Libraries' Digital Research and Curation Center.
A majority of these initial document sets reflect plaintiff and defendant exhibits and depositions submitted during the course of opioid litigation in individual states as well as the federal multi-district litigation (MDL 2804).These lawsuits argue that opioid manufacturers and distributors pursued manipulative and misleading marketing strategies, cast doubt on the addictiveness of the drug, and disregarded the significant risks to health, leading to a national opioid overdose epidemic and public health crisis.
Topics covered include:
Evasion of DEA suspicious order monitoring compliance procedures; Purdue Pharma internal OxyContin budgets; the Oklahoma Health Care Authority Drug Utilization Review Board; investigations of use, abuse, misuse, and diversion of specific drugs (fentanyl, Nucynta); opioid marketing and sales strategies; inspections and audits.
Types of documents include:
Emails, memos, presentations, sales reports, budgets, audit reports, DEA briefings, meeting agendas and minutes, expert witness reports, and depositions by pharmaceutical company executives.
Entities represented include:
Insys Therapeutics, Inc.; Johnson & Johnson; Janssen Pharmaceuticals; Qualitest; Purdue Pharma; Teva Pharmaceuticals; Drug Enforcement Administration (DEA); Richard Sackler; Paul Goldenheim; Actavis; Mallinckrodt; McKesson; Cardinal Health; KeySource Medical; Walmart; Rite-Aid; CVS Pharmacy; Walgreens; Endo International; Healthcare Distribution Management Association (HDMA).